Drug intelligence / Profile preview

transforming growth factor beta 3 + dexamethasone sodium phosphate

Development stage: Unknown
Lead developer: TheiaNova
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Ophthalmic

Overview

TN-001 is a topical ophthalmic drug candidate being developed by TheiaNova for the treatment of progressive keratoconus. It is a combination of two active ingredients: recombinant human transforming growth factor beta-3 (TGF-β3) and dexamethasone sodium phosphate. The therapy works by transiently activating developmental pathways to induce corneal keratocytes to re-express embryonic collagen phenotypes and secrete new collagen. This regenerative process is intended to restore the biomechanical strength of the corneal stroma, thereby halting the progression of keratoconus. TN-001 is currently being evaluated in a Phase 1/2 clinical trial (NCT07388069) in Australia.

Other names: TGF-beta 3 + dexamethasone sodium phosphate

Targets

GR (Glucocorticoid receptor)TGFBR1

Beyond the preview

Go deeper on transforming growth factor beta 3 + dexamethasone sodium phosphate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on transforming growth factor beta 3 + dexamethasone sodium phosphate.

Explore the full profile